ReviewAnnals of neurology2024
Oropouche Virus: An Emerging Neuroinvasive Arbovirus.
Review in Annals of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Integrated in vivo and transcriptomic analyses of lethal Oropouche virus infection reveal suppression of pathogenic host responses by antiviral therapy.PLoS pathogens · 2026Article
- Arbovirus co-circulation and epidemiological convergence in a changing climate: challenges for surveillance, diagnosis and public health preparedness.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Review
- Pediatric Arboviral Infections in Europe: Epidemiology, Clinical Features, Diagnosis and Prevention.Viruses · 2026Review
- Emergence of Oropouche Virus, Venezuela, 2025.Emerging infectious diseases · 2026Article
- Comparative analysis of host responses to Oropouche viruses in placental cell infection models.PLoS neglected tropical diseases · 2026Article
- Pharmacological targeting of bunyavirus-induced synaptic impairment prevents neuronal hyperexcitability.Nature communications · 2026Article
- A novel mathematical model of seasonality in Oropouche virus transmission in Amazonas, Brazil.Journal of mathematical biology · 2026Article
- Response to the Letter by Guagliardo et al.Open forum infectious diseases · 2026Article
- Phylogeographic dynamics of oropouche virus in the Colombian Amazon: Evolutionary insights in a climatic context.PLoS neglected tropical diseases · 2026Article
- Oropouche Virus (OROV) Vaccine Development for Vulnerable Populations: Epidemiological Context, Challenges and Future Directions.Vaccines · 2026Review
- Auto-Abs against type I IFNs: Strong, common, and global determinants of severe arboviral diseases.Journal of human immunity · 2026Review
- Review
- Article
- Case series of Oropouche fever among travellers returning from Cuba to Spain, 2024.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Article
- Oropouche virus efficiently replicates and is immunostimulatory in vivo in nonhuman primate species.Science advances · 2025Article
- The Role of Hematophagous Arthropods, Other than Mosquitoes and Ticks, in Arbovirus Transmission.Viruses · 2025Review
- Mysterious Oropouche virus: Transmission, symptoms, and control.Infectious medicine · 2025Review
- Solutions to expand microbiome sciences in the Caribbean Region: an insider's perspective.Trends in microbiology · 2025Article
- Re-emergence of Oropouche virus as a novel global threat.Current research in microbial sciences · 2025Review
- Insights into the expansion of Oropouche virus in Brazil: epidemiological and environmental aspects.Experimental biology and medicine (Maywood, N.J.) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Oropouche virus (OROV) is an arthropod-borne virus (arbovirus) in the Orthobunyavirus genus and Peribunyaviridae viral family that is endemic to parts of South America, Central America, and the Caribbean. It has recently emerged in Cuba, and travel-imported cases are recently being reported in the United States and Europe. Typically maintained in a sylvatic cycle between certain forest sloths, non-human primates, birds, and mosquitoes, OROV disease outbreaks can occur in an urban cycle between certain biting midges and/or mosquitoes and humans. Clinically, approximately 60% of infections are symptomatic with an abrupt fever and non-specific influenza-like illness within 3 to 10 days. Many initial OROV infections can present similarly to chikungunya, dengue, and Zika virus infections. Interestingly, OROV infections can follow a biphasic course with recurrence of symptoms approximately 1 week after initial symptom onset. Concerningly, similar to Zika virus, it appears that vertical transmission of OROV may occur with potentially adverse effects on fetal development including miscarriages. Neuroinvasion of OROV occurs in animal models, and human cases of meningitis, encephalitis, and peri-infectious Guillain-Barré syndrome have all been reported. Diagnosis is either through detection of OROV nucleic acid, OROV immunoglobulin M, or OROV neutralizing antibodies in the serum and/or cerebrospinal fluid. No antiviral treatments are available, and there are no current vaccines. Preventing mosquito and biting midge bites is key. Neurologists should be aware of and report any potential neuroinvasive OROV disease cases to local/state/territorial health departments. ANN NEUROL 2024.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.